Clinical Characteristics and Treatment Response of Peripheral Neuropathy in the Presence of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Experience at a Single Tertiary Center.
- Author:
Hye Jin CHO
1
;
Sehyo YUNE
;
Jin Myoung SEOK
;
Eun Bin CHO
;
Ju Hong MIN
;
Yeon Lim SEO
;
Byung Jae LEE
;
Byoung Joon KIM
;
Dong Chull CHOI
Author Information
- Publication Type:Original Article
- Keywords: eosinophilic granulomatosis with polyangiitis; peripheral neuropathy; cyclophosphamide; prognosis
- MeSH: Asthma; Cyclophosphamide; Eosinophilia; Eosinophils*; Follow-Up Studies; Granulomatosis with Polyangiitis*; Humans; Inflammation; Medical Records; Peripheral Nerves; Peripheral Nervous System Diseases*; Prognosis; Recurrence; Vasculitis
- From:Journal of Clinical Neurology 2017;13(1):77-83
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND PURPOSE: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic small-vessel vasculitis accompanied by asthma, eosinophilia, and eosinophilic inflammation of various tissues including the peripheral nerves. This study investigated the clinical course and long-term outcomes of peripheral neuropathy in patients with EGPA. METHODS: Seventy-one patients with physician-diagnosed EGPA were identified at Samsung Medical Center between January 1995 and April 2014. Sixty-one of these patients were followed-up for more than 1 year and received corticosteroid therapy with or without intravenous cyclophosphamide pulse therapy for 6 to 18 months. Medical records of the 61 patients including demographic data, clinical features, laboratory and pathological findings, treatments, and outcomes were reviewed. RESULTS: Peripheral neuropathy as a manifestation of EGPA was present in 46 (75%) of the 61 patients. The mean follow-up duration of the patients with neuropathy was 6.4 years (range 1.2–18.8 years). The scores on the neurological functional disability scale before and after the combination treatment with corticosteroid and cyclophosphamide were 2.43±0.86 and 0.54±0.95 (mean±SD; p<0.001), respectively. The peripheral neuropathy relapsed in one patient. CONCLUSIONS: The long-term clinical outcome of peripheral neuropathy in patients with EGPA receiving initial corticosteroid and cyclophosphamide combination therapy was favorable with a very low relapse rate.
